Journal article
Learning from the proteasome: how to fine-tune cancer immunotherapy
- Abstract:
-
Cancer immunotherapy has recently emerged as a forefront strategy to fight cancer. Key players in antitumor responses are CD8+ cytolytic T lymphocytes (CTLs) that can detect tumor cells that carry antigens, in other words, small peptides bound to surface major histocompatibility complex (MHC) class I molecules. The success and safety of cancer immunotherapy strategies depends on the nature of the antigens recognized by the targeted T cells, their strict tumor specificity, and whether tumors a...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 1.9MB)
-
- Publisher copy:
- 10.1016/j.trecan.2017.07.007
Authors
Bibliographic Details
- Publisher:
- Cell Press Publisher's website
- Journal:
- Trends in Cancer Journal website
- Volume:
- 3
- Issue:
- 10
- Pages:
- 726-741
- Publication date:
- 2017-08-24
- Acceptance date:
- 2017-07-24
- DOI:
- EISSN:
-
2405-8025
- ISSN:
-
2405-8033
- Pmid:
-
28958390
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:734488
- UUID:
-
uuid:84939cf6-9539-48e5-99b0-1595e8f40b2d
- Local pid:
- pubs:734488
- Source identifiers:
-
734488
- Deposit date:
- 2017-11-09
Terms of use
- Copyright holder:
- Elsevier Inc
- Copyright date:
- 2017
- Notes:
- Copyright © 2017 Elsevier Inc. This is the accepted manuscript version of the article. The final version is available online from Cell Press at: https://doi.org/10.1016/j.trecan.2017.07.007
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record